GSK to acquire CMG1A46 from Chimagen Biosciences
GSK (GSK) plc and Chimagen Biosciences, a privately held biotechnology company, announced an agreement for GSK to acquire ...
The Pharma Letter12d
GSK buys T cell-engager from Chimagen
UK pharma major GSK is to buy CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager (TCE), from privately-held ...
Pharmabiz11d
GSK inks agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline
GSK inks agreement to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline: London, UK Thursday, October 31, 2024, 10:00 Hrs [IST] GSK plc and Chimagen Bioscien ...
Yahoo Finance27d
BullFrog AI Strengthens Scientific Advisory Board with the Addition of GSK Veteran and Industry Pioneer Dr. John Baldoni
Dr. Baldoni’s career includes 29 years in R&D at GSK, where he served as Senior Vice President of Platform and Technology Sciences, leading critical innovations in drug discovery and development.
Stockhouse27d
BullFrog AI Strengthens Scientific Advisory Board with the Addition of GSK Veteran and Industry Pioneer Dr. John Baldoni
Dr. Baldoni’s career includes 29 years in R&D at GSK, where he served as Senior Vice President of Platform and Technology Sciences, leading critical innovations in drug discovery and ...
Bisnow6d
As VC Targets Life Sciences, Can Golden Triangle Shine Again?
The heat has been out of the life sciences market over the last 18 months, but new VC investments could fuel a comeback for ...
manilatimes27d
BullFrog AI Strengthens Scientific Advisory Board with the Addition of GSK Veteran and Industry Pioneer Dr. John Baldoni
GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BullFrog AI, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial ...